AGN

Market cap $53.542B
Enterprise value $77.168B
Employees 17,800
Revenue $15.9B
EBITDA $7.27B
Income -$4B
Book/Share 208.64
Price/Book 0.78
Cash/Share 19.52
Price/Sales 3.36
Debt/Equity 40.73
EPS -13.20
P/E 5.09
Forward P/E 9.78
EV/EBITDA 10.62
PEG 1.38
Earnings date 2018-05-07
Volume 2.58M / 3.08M
Relative vol. 0.84 ×
Profit margin -25.88%
Oper. margin -0.63%
Gross margin 86.40%
Sales Q/Q 21.08%
Sales Y/Y 12.12%
Est. EPS Q/Q 0.90%
Beta 1.30
Mean Recomm. 2.10
IPO year 2013
Country Ireland
RSI 37.76
Range $160.05 – $162.56
52 weeks $156.00 – $256.80
SMA 50 $173 +6.88%
SMA 200 $190 +16.99%
1 year target $218 +34.46%

Intraday

5 days

1 month

3 months

6 months

1 year

5 years

10 years

All time

Friday, 23 February 2018
+0.35%
finance.yahoo
Comparing Eli Lilly’s Post-4Q17 Valuation
Thursday, 22 February 2018
-0.19%
marketrealist
A Look at Eli Lilly’s Neuroscience Portfolio in 4Q17
marketrealist
Eli Lilly’s Human Pharmaceutical Portfolio in 4Q17
Wednesday, 21 February 2018
-0.59%
finance.yahoo
Novartis Expects FDA and EMA Approvals for Aimovig in 2018
Friday, 16 February 2018
-0.19%
realmoney.thestreet
Jim Cramer: Drug Stocks on the Move
prnewswire
Allergan Presents Data at the 2018 American Academy of Dermatology Annual Meeting in San Diego
finance.yahoo
United Therapeutics reaches patent settlement with Actavis
finance.yahoo
United Therapeutics settles patent litigation over $157M drug
markit
See what the IHS Markit Score report has to say about Allergan plc.
Thursday, 15 February 2018
-2.18%
finance.yahoo
Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'
finance.yahoo
How Pfizer’s Peri-LOE Products Performed in 2017
Wednesday, 14 February 2018
+6.01%
finance.yahoo
Behind Pfizer’s Internal Medicines in 2017
Monday, 12 February 2018
-0.96%
finance.yahoo
What Could Drive Amgen’s Long-Term Growth?
Sunday, 11 February 2018
wsj
New Tax Law Haunts Companies That Did ‘Inversion’ Deals
Saturday, 10 February 2018
finance.yahoo
OxyContin maker will stop promoting opioids to doctors
Thursday, 8 February 2018
-3.77%
benzinga
The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease
marketexclusive
Array BioPharma and Allergan Just Scored Big On Phase III Data
Tuesday, 6 February 2018
+1.22%
thestreet
Centene, LabCorp Among Healthcare Stock Gainers
thestreet
Allergan CEO: We Are Staying in Ireland
yahoo video
Lulu CEO departs, GM up after earnings, Allergan's forecast disappoints
thestreet
Stocks Trade Wildly, Dow Falls but Comes Off Early Plunge
yahoo video
Charts of the Day: Lululemon, GM, Allergan
investors
Allergan Pops On Consensus-Topping Quarter, Strong Migraine Trial
zacks
Allergan Q4 Earnings Beat on Increase in Botox Sales
reuters
Allergan's profit beats; migraine drug succeeds in key study
wsj
Stocks to Watch: Boeing, Netflix, GM, Lululemon, Micron, Skyworks, Pfizer, ADM
zacks
Allergan Beats Q4 Earnings & Sales, Stock Up
realmoney.thestreet
A Regular Winning Trade Becomes Roadkill in Market Meltdown
marketwatch
Allergan shares rise after Q4 profit, revenue beats
marketwatch
Allergan shares surge after positive late-stage migraine drug results
cnbc
Allergan smashes earnings estimates, says a trial for its migraine drug succeeds
prnewswire
Allergan Reports Solid Finish to 2017 with 12% Increase in Fourth Quarter GAAP Net Revenues to $4.3 Billion
accesswire
Allergan plc to Host Earnings Call
prnewswire
Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Monday, 5 February 2018
-4.01%
wsj
Allergan Names Matthew Walsh New Finance Chief
marketwatch
Allergan names current Catalent CFO as its CFO
prnewswire
Matthew M. Walsh Appointed Executive Vice President and Chief Financial Officer of Allergan plc
thestreet
Allergan's Pipeline Matters More Than Its Earnings Do: RBC
Friday, 2 February 2018
-2.94%
reuters
Allergan completes restructuring, pushes hard in China
zacks
Teva Completes Sale of Women's Health Segment for $703M
zacks
Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod
Thursday, 1 February 2018
-0.80%
marketrealist
A Look at Cara Therapeutics’ Intravenous CR845
prnewswire
FDA Approves AVYCAZ® for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
reuters
FDA approves Allergan's Avycaz for two types of pneumonia
zacks
Allergan to Report Q4 Earnings: What's in the Cards?
marketrealist
Johnson & Johnson’s Recent Developments
reuters
Allergan to pay Israel's Teva Pharm $700 million to settle dispute
marketwatch
Allergan will pay Teva $700 mln to settle dispute
globenewswire
New Research: Key Drivers of Growth for Guess?, Acer Therapeutics, American National Insurance, J P Morgan Chase, Juno Therapeutics, and Allergan — Factors of Influence, Major Initiatives and Sustained Production
Wednesday, 31 January 2018
-2.21%
prnewswire
Allergan to Present at The Leerink Partners 7th Annual Global Healthcare Conference
marketrealist
Eli Lilly’s 4Q17 Estimates: Elanco
prnewswire
Allergan Introduces "Not Cool vs. Cool" Multi-Channel Campaign for CoolSculpting® and Professional Athlete Brand Ambassadors: Figure Skater Johnny Weir and Golfer Ian Poulter
Tuesday, 30 January 2018
+0.12%
yahoo video
Allergan CEO: Wonderful to see how Bezos, Buffett and Dim...
Monday, 29 January 2018
-1.39%
thestreet
Rivals Unlikely to Knock Allergan's Botox Off its Perch: Analyst
simplywall.st
Is Allergan plc Undervalued?
benzinga
Barclays Injects Allergan With An Upgrade, Says Valuation Model Has Improved
Monday, 29 January 2018
-1.39%
smarteranalyst
Pernix Therapeutics Holdings Inc Reaches Settlement in Zohydro Patent Litigation
Friday, 26 January 2018
-0.17%
marketrealist
Pfizer’s 4Q17 Estimates: Products with Lower Sales
marketrealist
What to Expect for Novartis’s Subsidiary Alcon in 2018
marketexclusive
New York City Sues Big Pharma For Opioid Epidemic, But Does The Lawsuit Make Sense?
Thursday, 25 January 2018
+0.07%
thestreet
Allergan's Botox Business Could Stave Off Competition by Inking This Deal: RBC
Tuesday, 23 January 2018
-1.28%
thestreet
When to Buy Stock in Nvidia, Allergan and Tesla: Must-See Charts
zacks
Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb
zacks
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
Monday, 22 January 2018
+3.95%
yahoo video
Big pharma on a buying spree as Celgene buys Juno and San...
marketrealist
Merck & Co.’s Animal Health Business in 3Q17
fool
Whom Will Pfizer Buy in 2018?
Friday, 19 January 2018
+0.25%
bizjournals
Why this East Bay drug maker's stock price nearly doubled last year
zacks
Amgen/Allergan's Avastin Biosimilar Secures EU Approval
marketrealist
Johnson & Johnson’s Revenue Estimates for 4Q17
Thursday, 18 January 2018
+1.34%
prnewswire
European Commission Approves Amgen And Allergan's MVASI® For The Treatment Of Certain Types Of Cancer
marketrealist
How Amgen’s Biosimilars Are Positioned for 2018
thestreet
Allergan Could Raise $1 Billion From Anti-Infectives Sale - RBC Capital Markets
Wednesday, 17 January 2018
-1.52%
realmoney.thestreet
Allergan Needs More Time to Make a Proper Bottom
bizjournals
Judge approves settlement between Allergan shareholders and Ackman
Tuesday, 16 January 2018
+0.96%
wsj
Judge Signals He Will Approve Settlement Between Allergan Shareholders and Pershing, Valeant
reuters
Imprimis receives FDA warning over eye medication advertising
zacks
Teva's Trisenox Gets FDA Approval as First-Line Treatment
businesswire
Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS® Patent Litigation
Friday, 12 January 2018
-0.88%
ap
1st trial date set in state lawsuit over opioid epidemic
news.morningstar
Concerns About Allergan's Health Are Overblown
Thursday, 11 January 2018
+1.51%
thestreet
Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms
marketwatch
Ackman’s Pershing Square cuts hedge-fund fees due to lawsuit settlement
yahoo video
Pershing Square lowering management fees
Wednesday, 10 January 2018
-0.35%
marketrealist
What Analysts Recommend for Teva Pharmaceuticals
thestreet
3 Reasons Allergan Is Set Up for Success in 2018
investorplace
Treasury Bond Yield Pushes Ahead of the S&P 500
Tuesday, 9 January 2018
+2.43%
investorplace
Stocks Set for Record Run as Risks Multiply
reuters
U.S. pharma executives expect deals to pick up after tax overhaul
finance.yahoo
Judge urges action on '100 percent manmade' opioid crisis
simplywall.st
Allergan plc : What Does The Future Look Like?
zacks
Allergan's Sales Guidance for 2018 Lower Than Expected
yahoo video
Allergan CEO Saunders on the company's booming Botox busi...
yahoo video
Cramer's Stop Trading: Allergan's 'salami strategy'
cnbc
Stocks making the biggest moves premarket: TGT, AMZN, UAA, PYPL & more
investorplace
3 Stocks to Watch on Tuesday: A Schulman Inc, Allergan plc and Urban Outfitters, Inc.
bloomberg
How Allergan Continues to Make Drug Prices Insane
Monday, 8 January 2018
-1.39%
thestreet
Allergan CEO Saunders Says Stock Price Doesn't Reflect Company's True Value
reuters
Allergan forecasts 2018 revenue below estimates
prnewswire
Allergan Provides 2018 Preliminary Financial Outlook for Select Income Statement Categories and Other Updates at 36th Annual J. P. Morgan Conference
cnbc
After-hours buzz: AGN, URBN & more
prnewswire
Allergan to Report Fourth Quarter and Full Year 2017 Earnings and Host Conference Call and Webcast
Sunday, 7 January 2018
fool
2 Reasons Why Allergan Stock Plunged in 2017
Saturday, 6 January 2018
thestreet
America's Opioid Crisis Looks A Lot Big Tobacco Spats of Yesteryear
Friday, 5 January 2018
-0.08%
yahoo video
Feeding the beast with a bank earnings kicker
yahoo video
Cramer's game plan: Feeding the beast with a bank earning...
reuters
Future of Kala Pharma's dry eye drug uncertain after mixed results
zacks
Key Biosimilar Approvals in 2017: Progress Report
zacks
Pharma Stock Roundup: Allergan Announces Job Cuts, Pfizer Inks Deals
Thursday, 4 January 2018
+0.22%
zacks
Allergan to Cut Jobs Amid Loss of Exclusivity for Key Drugs
Wednesday, 3 January 2018
-1.08%
bloomberg
Pershing Square, Valeant Ordered to Defend Allergan Settlement
thestreet
Allergan to Cut More Than 1,000 Jobs
investorplace
Allergan plc Layoffs: Company Plans 1,000+ Job Cuts
Date
#
Company
Insider Title
Trans.
Transaction
Shares Price per share Total price Shares after Source
2017-12-06 Brent L Saunders
Chairman, President and CEO
Chairman, President and CEO Buy 4,600 $164.74 $757,804
2017-12-06
186,377
2017-12-05 Christopher J Coughlin
Director
Director Buy 10,000 $163.30 $1,633,000
2017-12-05
14,446
2017-12-01 William Meury
Chief Commercial Officer
Chief Commercial Officer Option exercise 11,807 $78.88 $931,336
2017-12-01
68,828
2017-05-18 Nesli Basgoz
Director
Director Option exercise 1,889 $84.44 $159,507
2017-05-18
7,919
2017-05-03 Michael R Gallagher
Director
Director Option exercise 17,693 $245.25 $4,339,208
2017-05-03
20,272
2017-03-29 Brent L Saunders
Chairman, President and CEO
Chairman, President and CEO Buy 85 $242.66 $20,626
2017-03-29
131,178
2017-03-02 Paul Bisaro
Director
Director Sale 70,000 $246.68 $17,267,600
2017-03-02
235,900
2016-12-08 Nesli Basgoz
Director
Director Sale 500 $188.72 $94,360
2016-12-08
5,515
2016-12-08 William Meury
Chief Commercial Officer
Chief Commercial Officer Option exercise 11,807 $109.12 $1,288,380
2016-12-08
48,866
2016-11-21 Brent L Saunders
Chairman, President and CEO
Chairman, President and CEO Buy 5,250 $189.13 $992,933
2016-11-21
106,564
2016-11-11 Maria Teresa Hilado
Chief Financial Officer
Chief Financial Officer Buy 1,422 $210.64 $299,530
2016-11-11
13,379

Notable SEC filings of Allergan plc.

Date Contents
Source
2018-02-05 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
2018-02-01 8-K Results of Operations and Financial Condition; Other Events
2018-01-08 8-K Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits
2018-01-03 8-K Results of Operations and Financial Condition; Regulation FD Disclosure
2018-01-02 8-K Entry into a Material Definitive Agreement; Material Modifications to Rights of Security Holders; Financial Statements and Exhibits
2017-12-18 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
2017-12-18 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
2017-11-02 10-Q Quarterly report
2017-11-01 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-09-25 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
2017-08-09 10-Q Quarterly report
2017-08-03 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-07-21 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
2017-05-26 8-K Entry into a Material Definitive Agreement; Other Events; Financial Statements and Exhibits
2017-05-25 8-K Other Events; Financial Statements and Exhibits
2017-05-24 8-K Other Events; Financial Statements and Exhibits
2017-05-23 8-K Other Events; Financial Statements and Exhibits
2017-05-10 8-K Other Events; Financial Statements and Exhibits
2017-05-09 10-Q Quarterly report
2017-05-09 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-05-05 8-K Submission of Matters to a Vote of Security Holders
2017-04-18 8-K Other Events
2017-02-24 10-K Yearly report
2017-02-08 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-02-03 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Other Events
2017-01-06 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Buy SunTrust Robinson Humphrey 22 February 2018
Buy → Buy Bank of America 6 February 2018
Outperform → Outperform Leerink Swann 6 February 2018
Outperform → Outperform Credit Suisse 6 February 2018
Equal-Weight → Overweight
Barclays 28 January 2018
Buy → Hold
Argus 6 December 2017
Equal-Weight → Overweight
Morgan Stanley 28 November 2017
Buy → Neutral
Mizuho 18 October 2017
Buy Citigroup 18 October 2017
Buy → Hold
Edward Jones 17 October 2017
Buy UBS 16 October 2017
Buy Deutsche Bank 16 July 2017
Neutral Cantor Fitzgerald 15 June 2017
Buy → Neutral
Goldman 9 May 2017
Neutral
Goldman Sachs 9 May 2017

Allergan plc executives

Insider Title Age Since Compensation
Brenton Saunders (47)
Chairman of the Board, President, Chief Executive Officer since 2016
Chairman of the Board, President, Chief Executive Officer 47 2016 $4,139,030
Paul Bisaro (56)
Director since 2016
Director 56 2016 $2,562,440
William Meury (49)
Chief Commercial Officer since 2016
Chief Commercial Officer 49 2016 $1,686,050
Catherine Klema (58)
Independent Director since 2016
Independent Director 58 2016 $499,794
Fred Weiss (75)
Independent Director since 2013
Independent Director 75 2013 $479,794
Ronald Taylor (69)
Independent Director since 2013
Independent Director 69 2013 $473,794
Christopher Bodine (61)
Independent Director since 2013
Independent Director 61 2013 $473,794
Nesli Basgoz (59)
Independent Director since 2014
Independent Director 59 2014 $473,794
Patrick O'Sullivan (75)
Independent Director since 2013
Independent Director 75 2013 $449,794
Peter McDonnell (58)
Independent Director since 2015
Independent Director 58 2015 $449,794
James Bloem (66)
Independent Director since 2013
Independent Director 66 2013 $449,794
Christopher Coughlin (64)
Lead Independent Director since 2016
Lead Independent Director 64 2016 $449,794
Karina Calzadilla
IR Contact Officer since 2017
IR Contact Officer 2017
Adriane Brown (58)
Independent Director since 2017
Independent Director 58 2017
Joseph Boccuzi
Director since 2017
Director 2017
A. Robert Bailey (53)
Chief Legal Officer and Corporate Secretary since 2016
Chief Legal Officer and Corporate Secretary 53 2016
C. Nicholson (62)
Chief R&D Officer since 2015
Chief R&D Officer 62 2015
James D'Arecca (46)
Chief Accounting Officer since 2013
Chief Accounting Officer 46 2013
Wayne Swanton
Executive Vice President - Global Operations since 2017
Executive Vice President - Global Operations 2017
Karen Ling (53)
Chief Human Resource Officer since 2016
Chief Human Resource Officer 53 2016
Allergan plc. logo

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

  • Allergan plc., Clonshaugh Business and Technology Park, Dublin D17 E400, Ireland
  • allergan.com
  • 862 261 7000

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

Balance sheet

(in millions) 2017Q4 2017Q3 2017Q2 2017Q1
Current assets
Cash $1,817.2 $1,612.7 $886.9 $1,092.9
Short term investments $4,632.1 $3,829.1 $4,939 $7,858.2
Net receivables $2,899 $2,808.6 $2,795.9 $2,542
Inventory $904.5 $899.8 $935.9 $904.7
Other current assets $1,123.9 $962.6 $875.5 $1,302.9
Total current assets $11,376.7 $10,112.8 $10,433.2 $13,700.7
Long term investments $267.9 $269.9 $290.2 $283.2
Property, plant & equipment $1,867 $1,813.3 $1,761.2 $1,686.3
Goodwill $49,862.9 $49,770.9 $49,592.2 $47,917.1
Intangible assets $54,648.3 $56,698.9 $62,369.7 $62,994.2
Other assets $81.6 $531.3 $497.6 $469.7
Deferred long term asset charges $319.1 $327 $288.3 $255.4
Total assets $118,341.9 $118,992.8 $124,734.8 $126,836.9
Current liabilities
Accounts payable $5,616.3 $4,762.8 $4,843.3 $4,865.2
Short long term debt $4,231.8 $3,797 $3,795 $5,526.4
Other current liabilities $5,616.3 $1,000 $923.2 $1,310.4
Total current liabilities $9,848.1 $8,559.8 $8,638.3 $10,391.6
Long term debt $27,417.4 $27,450.5 $27,339.4 $27,137.5
Other liabilities $886.9 $1,007 $1,038.3 $1,060.5
Deferred long term liabilities $6,352.4 $10,802 $12,486 $13,048.5
Minority interest $16 $14.1 $12.4 $10.4
Total liabilities $44,520.8 $47,833.4 $49,514.4 $51,648.5
Stockholders' equity
Stock option warrants
Common stock $73,837.1
Retained earnings $12,957.2 $10,137.2 $14,397.9 $15,429.9
Treasury stock $1,711.2 $1,625 $721.7
Capital surplus $54,013.5 $54,381.3 $54,267.8 $54,107.1
Other stockholder equity $1,920.7 $1,711.2 $1,625 $721.7
Total stockholder equity $73,821.1 $71,159.4 $75,220.4 $75,188.4
Net tangible assets -$30,690.1 -$35,310.4 -$36,741.5 -$35,722.9
(in millions) 2017 2016 2015
Current assets
Cash $1,817.2 $1,724 $1,096
Short term investments $4,632.1 $11,501.5 $9.3
Net receivables $2,899 $2,531 $2,125.4
Inventory $904.5 $718 $757.5
Other current assets $1,123.9 $1,383.4 $4,590.9
Total current assets $11,376.7 $17,857.9 $8,579.1
Long term investments $267.9 $282.1 $408.7
Property, plant & equipment $1,867 $1,638.3 $12,244.6
Goodwill $49,862.9 $46,356.1 $46,465.2
Intangible assets $54,648.3 $62,618.6 $67,836.2
Other assets $81.6 $447.4 $11,059.3
Deferred long term asset charges $319.1 $233.3 $49.5
Total assets $118,341.9 $128,986.3 $135,583.3
Current liabilities
Accounts payable $5,616.3 $5,076.8 $4,202.3
Short long term debt $4,231.8 $2,797.9 $2,396.5
Other current liabilities $5,616.3 $1,253.9 $1,693.2
Total current liabilities $9,848.1 $7,874.7 $8,292
Long term debt $27,417.4 $30,857 $40,935.8
Other liabilities $886.9 $1,085 $1,797.4
Deferred long term liabilities $6,352.4 $12,969.1 $7,968.8
Minority interest $16 $7.8 -$2.1
Total liabilities $44,520.8 $52,793.6 $58,991.9
Stockholders' equity
Stock option warrants
Common stock $73,837.1
Retained earnings $12,957.2 $18,342.5 $3,647.5
Treasury stock -$1,038.4 -$494.1
Capital surplus $54,013.5 $53,958.9 $68,508.3
Other stockholder equity $1,920.7 -$1,038.4 -$494.1
Total stockholder equity $73,821.1 $76,192.7 $76,591.4
Net tangible assets -$30,690.1 -$32,782 -$37,710

Income statement

(in millions) 2017Q4 2017Q3 2017Q2 2017Q1
Revenue
Total revenue $4,326.1 $4,034.3 $4,007.4 $3,572.9
Cost of revenue $580.9 $586.5 $550.2 $450.4
Gross profit $3,745.2 $3,447.8 $3,457.2 $3,122.5
Operating expenses
Research & development $408.2 $442.6 $489.4 $759.9
Selling, general & administrative $1,266.8 $1,169.7 $1,395 $1,185.2
Non-recurring $238.5 $4,076.8 $717.3 $347.4
Other operating expenses $1,922.2 $1,781 $1,757.9 $1,736
Total operating expenses $3,835.7 $7,470.1 $4,359.6 $4,028.5
Operating income -$90.5 -$4,022.3 -$902.4 -$906
Income from continuing operations
Net other income -$56 -$1,299.2 -$116.9 -$1,897.5
EBIT -$146.5 -$5,321.5 -$1,019.3 -$2,803.5
Interest expense $263.3 $265.2 $277.4 $289.7
Income before tax -$409.8 -$5,586.7 -$1,296.7 -$3,093.2
Income tax expense -$3,918.3 -$1,638.8 -$581.2 -$532.1
Minority interest $16 $14.1 $12.4 $10.4
Net income from continuing ops $3,508.5 -$3,947.9 -$715.5 -$2,561.1
Non-recurring events
Discontinued operations -$385.3 -$6.1 -$8.4 -$3.1
Extraordinary items
Effect of accounting change
Other items
Net income
EBITDA $3,121.3 -$3,955.7 -$725.9 -$2,565.2
Income (for common shares) $3,051.7 -$4,025.3 -$795.5 -$2,634.8
(in millions) 2017 2016 2015
Revenue
Total revenue $15,940.7 $14,570.6 $12,688.1
Cost of revenue $2,168 $1,860.8 $2,751.8
Gross profit $13,772.7 $12,709.8 $9,936.3
Operating expenses
Research & development $2,100.1 $2,575.7 $2,358.5
Selling, general & administrative $5,016.7 $4,740.3 $4,481.5
Non-recurring $5,380 $748.9 $783.6
Other operating expenses $7,197.1 $6,470.4 $5,443.7
Total operating expenses $19,693.9 $14,535.3 $13,067.3
Operating income -$5,921.2 -$1,825.5 -$3,131
Income from continuing operations
Net other income -$3,369.6 $289.1 -$223.2
EBIT -$9,290.8 -$1,536.4 -$3,354.2
Interest expense $1,095.6 $1,295.6 $1,193.3
Income before tax -$10,386.4 -$2,832 -$4,547.5
Income tax expense -$6,670.4 -$1,897 -$1,605.9
Minority interest $16 $7.8 -$2.1
Net income from continuing ops -$3,716 -$935 -$2,941.6
Non-recurring events
Discontinued operations -$402.9 $15,914.5 $6,861
Extraordinary items
Effect of accounting change
Other items
Net income
EBITDA -$4,125.5 $14,973.4 $3,915.2
Income (for common shares) -$4,403.9 $14,695 $3,683.2

Cash flow

(in millions) 2017Q4 2017Q3 2017Q2 2017Q1
Net income $3,121.3 -$3,955.7 -$725.9 -$2,565.2
Operating activities
Depreciation $1,984.2 $1,867.8 $1,863.9 $1,812.2
Net income adjustments -$3,899.5 $3,684.3 $34.4 $1,711.1
Change in accounts receivable -$49.8 $0.5 -$192.2 $53.2
Changes in liabilities $920.2 -$176.4 $706.1 -$239.9
Changes in inventory -$37.1 -$12.6 -$44.6 -$50.5
Changes in other operating activities $7.2 $62.8 -$14.4 $1.4
Total cash flow from operations $2,048.4 $1,472.4 $1,629.3 $723.3
Investing activities
Capital expenditures -$115.9 -$96.8 -$104 -$33.2
Investments -$671.1 -$369 $3,142.2 $3,267.4
Other cash flows from investing -$8.7 -$16.5 -$2,652.4 -$3,220
Total cash flows from investing -$795.7 -$482.3 $385.8 $14.2
Financing activities
Dividends paid -$301.2 -$305.1 -$306.1 -$305.8
Sale and purchase of stock -$440.4 $41.3 $66.4 $23.1
Net borrowings -$309.4 $2 -$1,540.3 -$1,015.9
Other cash flows from financing $3.6 -$10.1 -$428.8 -$76.3
Total cash flows from financing -$1,050.5 -$271.9 -$2,226.3 -$1,374.9
Effect of exchange rate $2.3 $7.6 $5.2 $6.3
Change in cash and equivalents $204.5 $725.8 -$206 -$631.1
(in millions) 2017 2016 2015
Net income -$4,125.5 $14,973.4 $3,915.2
Operating activities
Depreciation $7,528.1 $6,724.4 $7,486.5
Net income adjustments $1,530.3 -$19,531.7 -$5,527.6
Change in accounts receivable -$188.3 -$191 -$1,034.3
Changes in liabilities $1,210 -$13.1 $54.7
Changes in inventory -$144.8 -$268.4 -$226.2
Changes in other operating activities $57 -$254 -$66.4
Total cash flow from operations $5,873.4 $1,445.7 $4,606.1
Investing activities
Capital expenditures -$349.9 -$331.4 -$454.9
Investments $5,369.5 -$7,971.9 $858.7
Other cash flows from investing -$5,897.6 $32,636.6 -$37,524.7
Total cash flows from investing -$878 $24,333.3 -$37,120.9
Financing activities
Dividends paid -$1,218.2 -$278.4 -$208.1
Sale and purchase of stock -$309.6 -$14,904.3 $9,112.8
Net borrowings -$2,863.6 -$9,798.7 $25,003.5
Other cash flows from financing -$511.6 -$161.1 -$230.1
Total cash flows from financing -$4,923.6 -$25,142.5 $33,367.3
Effect of exchange rate $21.4 -$8.5 -$6.5
Change in cash and equivalents $93.2 $628 $846
Messenger